Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageNovanta Inc. and its subsidiaries (collectively referred to as the “Company”, “Novanta”, “we”, “us”, “our”) is a leading global supplier of core technology solutions that give medical, life science, and advanced industrial original equipment manufacturers (“OEMs”) a competitive advantage. We combine deep proprietary technology expertise and competencies in precision medicine, precision manufacturing, robotics and automation, and advanced surgery with a proven ability to solve complex technical challenges.
In the company’s own words · 10-K filed Feb 23, 2026 · SEC EDGAR
Business segments
Q1 2026 · $257.7MThe company’s own SEC segment disclosure.
- Robotics And Automation$84.2M33%
- Precision Medicine$63.9M25%
- Advanced Surgery$62.5M24%
- Precision Manufacturing$47.1M18%
Novanta Inc. (NOVT) reported revenue of $258M in Q1 2026 (quarter ended April 3, 2026), up 10% from the same quarter a year earlier. That came with a gross margin of 44% and net income of $21M (8.2% of revenue). For the full year FY2025, revenue was $981M (+3.3% year on year) and net income $54M. Its largest segment in 2026-Q1 was Robotics And Automation at $84M, 33% of the disclosed total, just ahead of Precision Medicine at 25%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Scientific & Technical Instruments
Ranks #16 of 16 by Smart Score